Recruiting
Phase 2

Baricitinib with Medication

Sponsor:

Stanford University

Code:

NCT06868381

Conditions

Cardiac Sarcoidosis

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Baricitinib (LY3009104) 4 mg

Study Details

Brief summary:

The goal of this clinical trial is to learn if baricitinib in combination with a background steroid-sparing medication can treat active cardiac sarcoidosis in adults. The main question it aims to answer is:

\- In patients with active cardiac sarcoidosis, does treatment with baricitinib improve cardiac sarcoidosis disease activity as assessed by changes on cardiac FDG-PET/CT?

Participants will:

  • Take baricitinib in combination with a steroid-sparing therapy for up to 16 weeks
  • Visit the clinic every two to four weeks for checkups and tests
  • Be asked to complete questionnaires to see how they feel on baricitinib and medication diaries to record when they take baricitinib

Conditions

Cardiac Sarcoidosis

Study ID

NCT06868381

Start date

Apr 1, 2026

Status verified date

Nov, 2026

Completion date

Dec 1, 2028

Anticipated

Primary completion date

Jul 1, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Key Inclusion Criteria:

  • Diagnosis of cardiac sarcoidosis based on one of the following pathways:

  • Histological Diagnosis

  • Myocardial or extracardiac biopsy demonstrating non-caseating granuloma with no alternative cause identified AND
  • Abnormal FDG uptake on cardiac PET-CT conducted within six weeks of Screening, in a pattern consistent with active cardiac sarcoidosis AND
  • Exclusion of other causes for cardiac manifestations
  • Clinical Diagnosis

  • One or more of the following is present:

  • Steroid +/- immunosuppressant responsive cardiomyopathy or heart block
  • Unexplained reduced LVEF (< 40%) and/or segmental wall motion abnormalities not related to coronary artery disease or another defined cause
  • Unexplained sustained (spontaneous or induced) VT
  • Mobitz type II 2nd degree heart block or 3rd degree heart block
  • CT chest and/or FDG PET-CT showing features consistent with pulmonary sarcoidosis and/or hilar lymphadenopathy AND
  • Abnormal FDG uptake on cardiac PET-CT conducted within 6 weeks of Screening, in a pattern consistent with active cardiac sarcoidosis AND
  • Exclusion of other causes for cardiac manifestations
  • Active cardiac sarcoidosis based on abnormal FDG uptake on cardiac PET-CT conducted within six weeks of Screening, in a pattern consistent with active cardiac sarcoidosis
  • No current treatment with immunosuppressive medications other than a steroid-sparing medication (including methotrexate, leflunomide, azathioprine, or mycophenolate mofetil), and/or prednisone (or equivalent) at a dose of ≤ 20mg daily at Baseline

Key Exclusion Criteria:

  • Receipt of a non-biologic DMARD or immunosuppressive agent other than methotrexate, leflunomide, azathioprine, mycophenolate mofetil, hydroxychloroquine, or glucocorticoids within 28 days prior to screening
  • Receipt of a bDMARD or tsDMARD, including non-depleting B-cell-directed therapy (eg, belimumab), T cell costimulatory blockade (eg, abatacept), TNF-alpha inhibition (eg, infliximab, adalimumab, etanercept, golimumab, certolizumab pegol), interleukin-6 inhibition (eg, tocilizumab, sarilumab), interleukin-1 inhibition (eg, anakinra), JAK inhibition (eg, tofacitinib, upadacitinib, baricitinib), or other biologic immunomodulatory agent within 28 days prior to screening
  • Receipt of any biologic B cell-depleting therapy (eg, rituximab, ocrelizumab, obinutuzumab, ofatumumab, inebilizumab) in the 6 months prior to screening; receipt of such a B cell-depleting agent in the period 6-12 months prior to screening is exclusionary unless B cell counts have returned to ≥ LLN
  • History of venous thromboembolism (VTE) or an increased risk for VTE
  • Current smoking
  • Estimated glomerular filtration rate < 30 mL/min/1.73 m2 by Modification of Diet in Renal Disease Study (MDRD) equation
  • Blood tests at screening that meet any of the following criteria:

  • Hemoglobin < 7.5 g/dL
  • Neutrophils < 1000/mm3
  • Absolute lymphocyte count < 500/mm3
  • Platelets < 100 x 109/L
  • Subjects with the following abnormal liver function tests:

  • Aspartate aminotransferase (AST) > 2x ULN
  • Alanine aminotransferase (ALT) > 2x ULN
  • Total bilirubin (TBL) > 2x ULN unless AST, ALT, and hemoglobin are within central laboratory normal range and the patient has a known history of Gilbert syndrome
  • Active, clinically significant infection at the time of Screening
  • Active malignancy or history of malignancy that was active within the last 5 years, except as follows:

  • In situ carcinoma of the cervix following apparently curative therapy > 12 months prior to screening,
  • Cutaneous basal cell or squamous cell carcinoma following apparently curative therapy, or
  • Prostate cancer treated with radical prostatectomy or radiation therapy with curative intent > 3 years prior to screening and without known recurrence or current treatment

Study Design

Enrollment

10 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: baricitinib + steroid-sparing drug +/- glucocorticoid taper

  • Participants will be treated with baricitinib 4 mg daily for up to 16 weeks in combination with a background steroid sparing medication
  • Participants who are on steroids at the time of enrollment will continue the steroid at a dose of prednisone (or equivalent) ≤ 20mg PO daily at Baseline and complete an 8 week taper of their steroid medication per a standardized protocol

Interventions

Baricitinib (LY3009104) 4 mg

baricitinib 4 mg tablet taken orally once daily

Primary outcome measure

  • Proportion of patients with resolution of cardiac FDG uptake on PET-CT [ Time Frame: From baseline to end of treatment at 16 weeks ]

Central Contacts and Locations

Central contacts

Locations

Stanford University

Recruiting

Palo Alto, California, United States, 94304-2210

Contacts

Principal Investigator:

Matthew C Baker, MD, MS

More Information

Sponsor

Stanford University

Last update posted

Nov 19, 2026

Last verified

Nov, 2026

Keywords

  • baricitinib
  • sarcoidosis
  • cardiac sarcoidosis
  • Janus kinase inhibitor
  • JAK inhibitor

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-20. This information was provided to ClinicalTrials.gov by Stanford University on 2026-11-19. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.